-
Immunochemical fecal occult blood testing (i-FOBT) is becoming increasingly popular as a screening tool for colorectal cancer (CRC).
-
Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
In a prospective, randomized, double-blind, placebo-controlled trial of women taking SRI's, sildenafil treatment resulted in a reduction of sexual side effects.
-
Peyronie's disease is an uncommon penile fibrotic disorder that most commonly affects young and middle-aged men. It is characterized by pain, deformity, or decreased capacity for intromission as a result of penile angulation.
-
In a large study of American adults, all-cause mortality was lowest for those with a body mass index (BMI) of 20.0-24.9 kg/m2.
-
Hepatitis A has been greatly reduced in the United States due to widespread vaccination, and most new cases are now the result of international travel.
-
The FDA has approved the first treatment for pseudobulbar affect (PBA).
-
A stroke "weekend effect" on mortality has been noted in studies reported from countries other than the United States.
-
The first oral contraceptive combined with a folate has been approved by the FDA.
-
The most recent advice from the U.S. Department of Agriculture (2005) recommends that the general population of adults not consume > 2300 mg/day of sodium, and that persons with hypertension (HTN) consume ≤ 1500 mg/day.
